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Abstract
Background—Diminished growth is highly prevalent among HIV-infected children and might 
be improved by antiretroviral therapy (ART). We examined growth recovery in a rural Ugandan 
cohort of HIV-infected children randomized to lopinavir/ritonavir or non-nucleoside-reverse-
transcription-inhibitor-based ART.
Methods—HIV-infected children 2 months to 6 years of age were randomized to Lopinavir/
ritonavir- or non-nucleoside-reverse-transcription-inhibitor-based ART. Changes in weight-for-age 
(WAZ), height-for-age (HAZ), and weight-for-height (WHZ) Z-scores for 24 months were 
evaluated using generalized linear repeated-measures models. Recovery from being underweight 
(WAZ<−2), stunted (HAZ<−2) and wasted (WHZ<−2) to Z-scores > −2 was also compared by 
arm using Kaplan-Meier survival and Cox proportional hazard modeling.
Results—A total of 129 children with median age of 3 years initiated therapy; 64 received 
Lopinavir/ritonavir-based and 65 non-nucleoside-reverse-transcription-inhibitor-based ART 
(nevirapine: 36 and efavirenz: 29). The median (IQR) difference in growth measures between 
baseline and 24 months for Lopinavir/ritonavir (n= 45) vs. non-nucleoside-reverse-transcription-
inhibitor-based therapy (n=40) were as follows, WAZ: 0.47 (0.10, 1.62) vs. 0.53 (0.03, 1.14) 
(p=0.59) and HAZ: median 1.55 (0.78, 1.86) vs. 1.19 (0.62, 1.65) (p=0.23), respectively. ART 
regimen was not predictive of change in WAZ (beta: −0.02, 95%CI: −0.25, 0.20) or HAZ (beta: 
0.05, 95%CI: −0.10, 0.19). Presence of confirmed virologic failure was not associated with 
growth.
Conclusions—Most ART-naive children experienced recovery of both WAZ and HAZ over the 
24 months following ART-initiation, with no significant difference between those receiving 
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Lopinavir/ritonavir vs. non-nucleoside-reverse-transcriptase-inhibitor-based ART. However, the 
persistence of median Z-scores below zero underscores the need for additional strategies to 
improve growth outcomes in HIV+ African children.
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Growth recovery; HIV infection; children; antiretroviral drugs
INTRODUCTION
Sub-optimal growth is highly prevalent among HIV-infected children, and is associated with 
high mortality risk (1). The impaired growth of HIV-infected children is likely the 
consequence of a combination of clinical and social factors including reduced caloric intake, 
reduced absorption and increased loss of nutrients needed for growth, altered metabolic 
rates, adverse socioeconomic conditions, and parental illness (2).
Antiretroviral therapy (ART) regimens have been one strategy to improve growth in HIV 
infected children, but different ART medications may affect growth differently. While some 
ART regimens have been shown to dramatically improve growth parameters (3-5), the 
results of two randomized trials suggested that the use of lopinavir/ritonavir (LPV/r) may 
lead to poorer growth outcomes among children (6, 7). Further, while ART is generally 
thought to improve growth, the precise impact of virologic failure on growth outcomes is not 
well documented. Some studies have reported robust growth responses despite failure to 
completely achieve virologic suppression on treatment (3, 8) while others report that 
virologic suppression may not be a requirement for initial growth responses in children (9, 
10).
Therefore, we sought to determine if ART regimen or the presence of virologic failure were 
associated with differential growth recovery in the context of a clinical trial in which HIV-
infected ART-naïve Ugandan children were randomized to initiate LPV/r- or non-nucleoside 
reverse-transcriptase inhibitor (NNRTI)-based ART.
MATERIALS AND METHODS
We evaluated children enrolled in the PROMOTE-pediatrics trial, an open-label, randomized 
trial in Tororo, Uganda (NCT00978068) that was conducted between 2009 to 2012. In this 
study, ART-naïve and -experienced HIV-infected children 2 months to 6 years of age were 
randomly assigned to either NNRTI -based or PI- based ART; details of the study protocol 
and results have been previously published (11). ART naïve children were excluded if they 
had received nevirapine for prevention of vertical transmission in the past 24 months. For 
children in the PI arm, lopinavir/ritonavir was used. For children in the NNRTI arm, NVP 
was used for children < 3 years of age; EFV was recommended for children ≥3 years of age, 
but choice of EFV vs NVP was left to provider discretion. At enrollment, children received 
ART, a long-lasting insecticide treated bed net, a hygienic water storage container, daily 
multivitamins and daily cotrimoxazole prophylaxis. Participants received all medical care at 
a study clinic. Children were given nutritional supplementation (Plumpy'Nut, Nutriset, 
Malaunay, France) at the discretion of the clinicians for severe malnutrition. Weight-for-age 
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(WAZ), height-for-age (HAZ), and weight-for-height-for-age (WHZ, for age < 60 months) 
were calculated for each visit using WHO supplied SAS macros (12). CD4 count and 
percentage, HIV RNA and hemoglobin levels were obtained every 12 weeks.
To evaluate growth recovery following ART initiation, we analyzed data for the 24 months 
following ART-initiation among ART-naive PROMOTE-pediatric enrollees using both as-
treated and intention-to-treat analysis. Baseline anthropometric measures were compared 
between arms using Wilcoxon rank sum or Fisher's exact tests. Changes in gender-specific 
Z-scores for WAZ and HAZ after baseline were evaluated using Generalized Estimating 
Equation (GEE) models that adjusted for (selected a priori) baseline Z-score, socioeconomic 
status, age (< or ≥ 3 years) and confirmed virologic failure (defined as the first of 2 
consecutive HIV RNA results > 400 copies/ml, 24 weeks after starting the regimen to which 
they had been randomized, and included as a time-varying covariate). To do this, we fitted a 
linear model (slope) to all time points up to month 24. The adequacy of assuming a linear 
relationship across time between the outcome and predictors in GEE models was assessed 
using a Kolmogorov-type supremum test comparing the distribution of the observed 
cumulative residual pattern to the distribution of computer-simulated cumulative residual 
patterns under a zero mean Gaussian process. We evaluated each GEE model's functional 
form for misspecification by using 10,000 simulated realizations. The model testing yielded 
p-values between 0.93 and 1.00 for all models, indicating all models were appropriately 
specified.
Socio-economic status (SES) was evaluated using a household assets measure that was 
created based on possession (or not) of a radio, telephone, television, refrigerator, 
motorcycle, bicycle, and car. To adjust for SES, the first two components of a principle 
component analysis of household assets, which accounted for 55.7% of the information 
contained in the asset holding variables, were used.
In addition to evaluating change over time including all children, nutritional recovery among 
children who were underweight (WAZ<−2), stunted (HAZ<−2) to Z-scores > −2 after 12 
months and 24 months was compared between ART treatment groups using Kaplan-Meier 
survival plots and Cox proportional hazard modeling. WHZ was not included in longitudinal 
analyses because the WHO only provides WHZ reference values up to age 60 months. [The 
lack of standards for WHZ after 60 months (12) would have led to truncated data in the 58% 
(75 of 129) of children who surpassed 5 years of age during the 24 month follow up period.] 
We also developed an integral measure of plasma HIV RNA exposure for each individual, an 
area under curve (AUC) for log HIV RNA level and time up to censoring or endpoint, 
irrespective of treatment status or randomized regimen adherence, and included this 
continuous measure as a predictor in the Cox-proportional modelling of recovery for 
children with nutritional Z-scores < −2 at enrollment. Statistical analyses were conducted 
using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) or Stata Version 11 (StataCorp, 
College Station, TX, USA).
The study was approved by Makerere University School of Medicine Research and Ethics 
Committee, Uganda National Council for Science and Technology, and University of 
California, San Francisco, Committee for Human Research.
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RESULTS
A total of 176 children were randomized to receive either NNRTI-based or LPV/r-based 
ART. Of these children, 129 were ART-naïve and initiated ART (Table 1). Children were a 
median age of 3 years old, with only 9 (7%) < 12 months. The majority (67%) were WHO 
clinical stage 1 at enrollment. All children in the PI arm initiated LPV/r (n=64). In the 
NNRTI arm (n=65), all children < 3 years of age received NVP (n=26); among children ≥ 3 
years of age, more received EFV (n=29) than NVP (n=10). The median CD4 % was 16 (IQR 
11 to 23) and HIV RNA log (copies/ml) was 5.3 (IQR 4.8 to 5.9) at baseline. The median 
(IQR) Z-scores did not significantly differ by arm (LPV/r vs. NNRTI) at baseline: WAZ 
[−1.5 (−2.4 to −0.6) vs. −1.2 (−2.3 to −0.6)], HAZ [−2.6 (−3.2 to −1.5) vs. −2.3 (−3.3 to 
−0.8)]. Among the 108 children ≤ 60 months; WHZ did not differ significantly between the 
treatment arms −0.2 (−1.1 to 0.6) vs. −0.1 (−0.9 to 0.5), p=0.97.
Of the total 129 children who initiated ART, 39 did not reach 24 months of follow-up: 7 
were lost to follow up and the other 32 remained enrolled but with < 24 months of follow-up 
time at the time the study ended. The median (IQR) follow-up times were 23.9 months 
(18.4, 23.9) for the LPV/r arm and 23.8 months (17.5, 23.9) for the NNRTI arm. The 24 
month confirmed virologic failure rate was 25% (16/64) in both the LPV/r arm and the 
NNRTI-arm (16/65; NVP: 11/25, EFV: 5/24). The proportion of failure estimated by 
Kaplan-Meier survival analysis at 24 months was 35% in the LPV/r Arm and 36% in the 
NNRTI arm (Log Rank P-value = 0.88).
In the first 24 months of follow-up, 11 children changed their ART regimen: 1 changed from 
NVP to LPV/r out of concern for possible Steven's Johnson Syndrome (week 3), 1 changed 
from NVP to EFV due to elevation of liver enzymes, 5 children switched from NNRTI to 
LPV/r due to virologic failure (weeks 53, 87, 91, 92, 92) and 1 child switched from LPV/r to 
NNRTI due to need for tuberculosis treatment (at week 58). Three children received 
nutritional supplementation (PI: 2, NNRTI: 1).
HAZ and WAZ of children in both arms increased steadily over 24 months following ART-
initiation (Figure 1). The median (IQR) difference in growth measures between baseline and 
24 months for Lopinavir/ritonavir (n= 45) vs. non-nucleoside-reverse-transcription-inhibitor-
based therapy (n=40) were; WAZ: 0.47 (0.10, 1.62) vs. 0.53 (0.03, 1.14) (p=0.59) and HAZ: 
1.55 (0.78, 1.86) vs. 1.19 (0.62, 1.65) (p=0.23), respectively. In multivariate models, ART 
regimen (LPV/r vs. NNRTI) was not predictive of change in WAZ or HAZ by either 
intention-to-treat (ITT) [WAZ, beta: −0.02, 95%CI:-0.32 to 0.29; or HAZ, beta: 0.13, 
95%CI: −0.09, 0.34) or as-treated analyses (PP) [WAZ, (beta: −0.05, 95%CI: −0.35, 0.26 ) 
or HAZ, (beta: 0.10, 95%CI: −0.10, 0.31). In ITT modelling, age < 3 years was associated 
with an additional mean increase of 0.67 Z-score points in the overall change in WAZ from 
baseline compared to age ≥ 3 years (beta: 0.67, 95%CI: 0.35 to 0.98) but not for HAZ (beta: 
0.06, 95%CI: 0.−0.16 to 0.27). SES was not a predictor of change in either WAZ or HAZ.
Among children who had Z-scores < −2 at baseline and reached 24 months of follow up, the 
crude proportions who recovered (from below −2 SD to above −2 SD) HAZ was 89% 
(23/26) vs. 76% (19/25), and the proportion who recovered WAZ was 85% (17/20) vs. 79% 
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(11/14), in the LPV/r vs. NNRTI arms respectively at 24 months. In Kaplan-Meier survival 
analysis, the proportion estimated to have recovered WAZ was 86% vs. 77% and the 
proportion who recovered HAZ was 89% vs. 76% in the LPV/r vs. NNRTI arms respectively 
at 24 months. Median time to recovery for HAZ did not differ between arms; it was 18.4 
months (IQR 12.0, 23.8) in both the LPV/r arm and in the NNRTI arm (IQR 12.0, 24.0), 
p=0.45. There was likewise no significant difference in the time to recovery for WAZ in the 
LPV/r (6.5 months, IQR 6.2, 18.4) vs. NNRTI (9.1 months, IQR 6.2, 23.4) arms (p=0.92). In 
Cox Proportional Hazards Modelling of time to recovery from below to above −2 HAZ or 
WAZ, presence of confirmed virologic failure, HIV RNA AUC and SES were not predictive 
of change in either HAZ or WAZ.
DISCUSSION
In this study of growth recovery in HIV-infected children initiating either NNRTI- or LPV/r-
based ART, we observed steady improvements in the HAZ and WAZ of children in both 
treatment arms over 24 months. This is consistent with dramatic and sustained improvement 
in growth responses after ART initiation, especially in younger children, previously 
observed in several other studies (4, 5, 10, 13, 14).
Our study did not demonstrate differential growth recovery among children receiving LPV/r- 
or NNRTI- based ART at 24 months of follow up, in contrast to data from other clinical 
trials that suggested LPV/r might lead to poorer growth at 12 months (5, 7, 15). In a cohort 
of infants exposed to nevirapine prophylaxis, median increases in z scores for height and 
weight were larger in the nevirapine group than in the LPV/r group at all study visits up to 
week 96, but the differences were not significant statistically (median increase in WAZ at 
48wks, 0.78 vs. 0.46; p=0.46, median increase in HAZ at 48wks 0.41 vs. 0.07, p=0.15) (15). 
In a parallel cohort of infants not exposed to nevirapine, mean values improved for all 
nutritional outcomes in both treatment groups, but between-group differences were 
significant only for adjusted changes in WAZ (p=0.01 at week 24 and p=0.01 at week 48), 
BMI (p=0.02 at week 24, p=0.03 at week 48), in favor of the nevirapine arm (7). Impaired 
growth in children receiving LPV/r might have resulted from gastrointestinal side effects, 
decreased caloric intake caused by GI disturbances, or altered metabolism. However, the 
differences were notably small and did not endure in these trials. In the context of these 
findings, we believe our results suggest that children in similar settings who are prescribed 
LPV/r might have slight differences in growth, but that they are unlikely to be durable or 
clinically significant.
The mechanisms by which ART contributes to growth recovery are not clear. One might 
postulate that the mechanism for growth recovery following ART is suppression of viral 
replication, in turn leading to relief from the metabolic costs of inflammation. However, 
improvement in HAZ and WAZ were notably independent of virologic response in our 
study. Reports from other studies have shown variable association of growth with virologic 
suppression. One trial found that a reduction in the viral load of at least 1.5 log and increase 
in CD4 cells was associated with improved growth recovery(5), but other studies have 
shown robust growth responses despite failure to completely suppress virus during treatment 
(8, 10). These results suggest that even suboptimal suppression of viral replication and CD4 
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recovery might provide enough of a metabolic benefit to improve growth (2, 16). Growth 
recovery in HIV children on ART may also result from other components of care provided 
including improved general medical care and cotrimoxazole prophylaxis, which would 
reduce risk of opportunistic infections.
One concern when initiating children on ART is that nutritional status might worsen. There 
have been reports of severe acute malnutrition (SAM) occurring in HIV infected children 
within the first 12 weeks following ART initiation (17). We did not document significant 
worsening of nutritional status following ART initiation. In these reports, it was postulated 
that observed SAM probably represented a form of immune reconstitution syndrome in 
children with underlying chronic malnutrition and severe immunosuppression.
In our cohort, a larger number of children had HAZ scores < −2 SD than WAZ <−2 at 
baseline. This is a common pattern (18), also noted in HIVNET 012 which showed a 2 to 4 
fold higher prevalence of HAZ < − 2 compared to WAZ (19). WAZ is considered to be a 
marker of recent nutritional insult, while low HAZ reflects chronic issues of health and 
nutrition (20). Studies have shown variable recovery of height after initiating ART (21). 
Kabue et al. reported improvement in HAZ at 1 year (p<0.05)(22); Mwiru et al. (2014) 
likewise found improvement in HAZ, but children's HAZ scores never normalized despite 
catch-up growth (14). Gsponer et al. (2012) found improvements in HAZ, but HAZ catch-up 
growth was slowest in first year of ARV treatment.
While our study has a number of important strengths, including randomized allocation of 
ART and close follow up, there were several limitations. It may be that the smaller sample 
size of our cohort and truncated follow-up time concealed small differences by arm, or that 
other characteristics of our cohort, such as its older age, altered the manifestation of the 
effects of LPV/r. Unfortunately, the study sample size and association of age with NNRTI 
choice in this cohort did not permit us to compare EFV to either LPV/r or NVP separately. 
The shorter median follow-up in our study (24 months) may have limited our ability to 
observe the long-term impact of virologic suppression growth and our determination of 
predictors of growth recovery in this population. Given that measurement of nutritional 
outcomes was not a primary aim of the study, nutritional supplementation was left to 
provider discretion and we did not document duration and quantity of supplementation. 
While this reflects standard local practice and adds to generalizability of our results, it limits 
our analytical ability to evaluate and adjust for supplementation as a factor in growth 
improvement. Several studies have demonstrated positive effects from supplementation, but 
there is a need for additional research (21).
In conclusion, our study demonstrated significant growth recovery for most HIV-infected 
African children initiating ART, and that children receiving LPV/r in similar settings can be 
expected to have comparable growth to children receiving NNRTI-based ART. However, that 
median nutritional Z-scores persisted below zero underscores the need for additional 
strategies to optimize growth outcomes in HIV positive African children.
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Figure 1. 
WAZ and HAZ trajectories among HIV-infected Ugandan children < 5 y, by ART regimen 
(n=129).
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Table 1
Subject characteristics at baseline
Characteristic LPV/r Arm (n=64*) NNRTI Arm (n=65*) P-value†
Age, years 3.2 (2.3 to 4.4) 3.1 (2.3 to 4.6) 0.97
< 3 years 29 (45%) 26 (40%) 0.56
Female 32 (30%) 35 (54%) 0.72
CD4 number, cells/μl 582 (397 to 969) 593 (389 to 788) 0.89
CD4 Percentage 17 (12 to 23) 16 (11 to 23) 0.77
HIV RNA, log(copies/ml) 5.3 (4.8 to 5.9) 5.3 (4.8 to 5.9) 0.75
WHO Stage 0.82
    I 39 (61%) 48 (74%)
    II 17 (27%) 11 (17%)
    III 2 (3%) 1 (2%)
    IV 6 (9%) 5 (8%)
WAZ −1.5 (−2.4 to −0.6) −1.2 (−2.3 to −0.6) 0.67
        WAZ < −2^ 24 (38%) 22 (34%) 0.66
HAZ −2.6 (−3.2 to −1.5) −2.3 (−3.3 to −0.8) 0.59
        HAZ < −2^ 39 (61%) 39 (60%) 0.91
WHZ~ −0.2 (−1.1 to 0.6) −0.1 (−0.9 to 0.5) 0.97
        WHZ~ < −2^ 7 (12%) 5 (8%) 0.48
*
Excludes the 2 children who withdrew or died before initiating study drugs.
†Wilcoxon rank sum, Fisher's Exact test, or test of proportions. Values are medians (interquartile range) or number (percentage); LPV/r, ritonavir-
boosted lopinavir; NNRTI, non-nucleoside-reverse-transcriptase-inhibitor. WAZ: Weight-for-age Z-score; HAZ: Height-for-age Z-score; WHZ: 
Weight-for-height-for-age Z-score.
~
Includes only the 107 of 129 who were age < 60 months at enrollment and therefore had WHO WHZ references.
^
Proportion (%) with Z-scores < −2 at baseline.
Pediatr Infect Dis J. Author manuscript; available in PMC 2017 December 01.
